PARP inhibitors

AstraZeneca Goes Up Against 2 Cancer Upstarts
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
Flag link:
In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo
In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo
Fierce Pharma
Roche
Tecentriq
bladder cancer
Zejula
PARP inhibitors
Flag link:
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer
Flag link:
A New PARP Drug For Breast Cancer
A New PARP Drug For Breast Cancer
Forbes
PARP inhibitors
breast cancer
metastatic breast cancer
talazoparib
Pfizer
Flag link:
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Endpoints
Pfizer
AstraZeneca
talazoparib
advanced breast cancer
Lynparza
PARP inhibitors
Flag link:
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
Flag link:
Clovis looks to expand label for PARP inhibitor
Clovis looks to expand label for PARP inhibitor
Biopharma Dive
Clovis Oncology
PARP inhibitors
Rubraca
Flag link:
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
AstraZeneca
Tesaro
Clovis Oncology
PARP inhibitors
drug pricing
ovarian cancer
Lynparza
Zejula
Rubraca
Flag link:
A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
Forbes
pancreatic cancer
PARP inhibitors
Clovis Oncology
Rubraca
Flag link:
Tesaro's Zejula rolls to No. 1 PARP position with big Q2
Tesaro's Zejula rolls to No. 1 PARP position with big Q2
Fierce Pharma
Tesaro
Zejula
PARP inhibitors
earnings
Flag link:
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Fierce Pharma
PARP inhibitors
AstraZeneca
Clovis Oncology
Tesaro
drug pricing
Flag link:
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Flag link:
Is Clovis Oncology A Takeover Candidate?
Is Clovis Oncology A Takeover Candidate?
Seeking Alpha
Clovis Oncology
M&A
rucaparib
PARP inhibitors
Flag link:
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Investors Business Daily
AstraZeneca
Clovis
Tesaro
PARP inhibitors
Flag link:
Tesaro's PARP inhibitor approved in ovarian cancer
Tesaro's PARP inhibitor approved in ovarian cancer
BioPharma Dive
Tesaro
ovarian cancer
PARP inhibitors
niraparib
Flag link:
AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial
AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial
Fierce Pharma
AstraZeneca
PARP inhibitors
Lynparza
FDA
ovarian cancer
clinical trials
Flag link:
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
TheStreet.com
Clovis Oncology
FDA
PARP inhibitors
rucaparib
ovarian cancer
Rubraca
Flag link:
AbbVie breast cancer drug falls short in Phase 2
AbbVie breast cancer drug falls short in Phase 2
BioPharma Dive
AbbVie
breast cancer
veliparib
PARP inhibitors
BRCA-mutant breast cancer
Flag link:
Gilead Sciences, Inc. Can Fancy TESARO Inc for Acquisition
Gilead Sciences, Inc. Can Fancy TESARO Inc for Acquisition
Bidness, ETC
Gilead Sciences
PARP inhibitors
Tesaro
M&A
niraparib
Flag link:
Buyout target Medivation says cancer drug could be "best in class"
Buyout target Medivation says cancer drug could be "best in class"
Yahoo/Reuters
Medivation
talazoparib
PARP inhibitors
Sanofi
M&A
Flag link:

Pages